Citizen Petitions Targeting ANDAs Recede, But Concerns Over Resources Remain
Executive Summary
FDA worries about diverting resources to respond to 505(q) petitions, despite receiving lowest number in fiscal year 2015 since it began tracking requests.
You may also be interested in...
US FDA Changing View Of Citizen Petition Response Time, Could Eliminate Serial Refiling
By aligning petition filing deadlines with user fee goals, agency could discourage petitions that need response within 150 days, potentially ending non-substantive response practice.
US FDA Changing View Of Citizen Petition Response Time, Could Eliminate Serial Refiling
By aligning petition filing deadlines with user fee goals, agency could discourage petitions that need response within 150 days, potentially ending non-substantive response practice.
US FDA Amps Up "Name And Shame" Approach To Thwart Anti-Generic Tactics
New draft guidance says citizen petition abuses will be referred to FTC and publicly called out as attempts to delay ANDA approvals.